The Chicago Entrepreneur

Gilead’s twice-yearly shot cut HIV infections by 96% in trial

The data sets the stage for likely approval of Gilead’s Lenacapavir for HIV prevention.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Coinbase’s wrapped Bitcoin token cbBTC goes live
Next post SpaceX performs historic first spacewalk with Polaris Dawn crew